Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia

References

• ElterTHallekMEngertAFludarabine in chronic lymphocytic leukaemiaExpert Opin Pharmacother20067121641165116872267
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• MirMAChronic lymphocytic leukemia: practice essentials, pathophysiology, etiologyEmedicinemedscapecom2016 [Updated September 7, 2016]. Available from: http://emedicine.medscape.com/article/199313-overviewAccessed August 12, 2016
   Google Scholar
• RokoszLLBeasleyJRCarrollCDKinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challengesExpert Opin Ther Targets200812788390318554156
   PubMed Web of Science ®Google Scholar
• KurosakiTHikidaMTyrosine kinases and their substrates in B lymphocytesImmunol Rev2009228113214819290925
   PubMed Web of Science ®Google Scholar
• HallekMChesonBDCatovskyDGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesBlood2008111125446545618216293
   PubMed Web of Science ®Google Scholar
• EichhorstBFBuschRStilgenbauerSFirst-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBlood2009114163382339119605849
   PubMed Web of Science ®Google Scholar
• WoyachJARuppertASRaiKImpact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential Cancer and Leukemia Group B studiesJ Clin Oncol201331444044723233702
   PubMed Web of Science ®Google Scholar
• HillmenPRobakTJanssensAChlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialLancet201538599801873188325882396
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus Chloram-bucil in patients with CLL and coexisting conditionsN Engl J Med2014370121101111024401022
   PubMed Web of Science ®Google Scholar
• NordstromBLKnopfKBTeltschDYEngleRBeygiHStercheleJAThe safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysisLeuk Lymphoma20145561266127323987821
   PubMed Web of Science ®Google Scholar
• SalvanaEMSalataRAInfectious complications associated with monoclonal antibodies and related small moleculesClin Microbiol Rev200922227429019366915
   PubMed Web of Science ®Google Scholar
• ChaoCPageJHYangSJRodriguezRHuynhJChiaVMHistory of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxisAnn Oncol20142591821182924915871
   PubMedGoogle Scholar
• Dunn-WaltersDThiedeCAlpenBSpencerJSomatic hypermutation and B-cell lymphomaPhilos Trans R Soc Lond B Biol Sci20013561405738211205334
   PubMedGoogle Scholar
• HamblinTJDavisZGardinerAOscierDGStevensonFKUnmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemiaBlood19999461848185410477713
   PubMed Web of Science ®Google Scholar
• GreippPTSmoleySAViswanathaDSPatients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosisBr J Haematol2013163332633324032430
   PubMed Web of Science ®Google Scholar
• RivlinNBroshROrenMRotterVMutations in the p53 tumor suppressor geneGenes Cancer20112446647421779514
   PubMedGoogle Scholar
• AbrisquetaPCrespoMBoschFPersonalizing treatment for chronic lymphocytic leukemiaExpert Rev Hematol201141273521322776
   PubMed Web of Science ®Google Scholar
• StratiPKeatingMJO’BrienSMOutcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletionHaematologica20149981350135524859876
   PubMed Web of Science ®Google Scholar
• SchnaiterAStilgenbauerS17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approachHematol Oncol Clin North Am201327228930123561474
   PubMedGoogle Scholar
• LangerbeinsPBahloJRheinCThe CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progressionFuture Oncol201511131895190326161926
   PubMed Web of Science ®Google Scholar
• MedlinePlus. Ibrutinib. National Institutes of Health, U.S. National Library of Medicine [updated September 15, 2015]. Available from: https://medlineplus.gov/druginfo/meds/a614007.htmlAccessed August 12, 2016
   Google Scholar
• PanZScheerensHLiSJDiscovery of selective irreversible inhibitors for Bruton’s tyrosine kinaseChemMedChem200721586117154430
   PubMed Web of Science ®Google Scholar
• de JongJSukbuntherngJSkeeDThe effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemiaCancer Chemother Pharmacol201575590791625724156
   PubMed Web of Science ®Google Scholar
• Pharmacyclics. Imbruvica® (ibrutinib)Sunnyvale, CAPharmacyclics2016 Available from: https://www.imbruvica.com/docs/librariesprovider7/default-document-library/prescribing_information.pdfAccessed August 12, 2016
   Google Scholar
• ZouYXiaoJTuZStructure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton’s tyrosine kinase inhibitorsBioorg Med Chem Lett201626133052305927210433
   PubMed Web of Science ®Google Scholar
• BrownJRHillmenPO’BrienSUpdated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATE™ trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphomaBlood2014124213331
   Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA expands approved use of Imbruvica for chronic lymphocytic leukemiaU.S. Department of Health and Human Services [Updated July 28, 2014] Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406916.htmAccessed August 12, 2016
   Google Scholar
• BurgerJAKeatingMJWierdaWGSafety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyLancet Oncol201415101090109925150798
   PubMed Web of Science ®Google Scholar
• JaglowskiSMJonesJAFlynnJMA phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseasesJ Clin Oncol201230suppl 156508
   Google Scholar
• BurgerJATedeschiABarrPMIbrutinib as initial therapy for patients with chronic lymphocytic leukemiaN Engl J Med2015373252425243726639149
   PubMed Web of Science ®Google Scholar
• ByrdJCFurmanRRCoutreSETargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaN Engl J Med20133691324223782158
   PubMed Web of Science ®Google Scholar
• McMullenJRBoeyEJOoiJYSeymourJFKeatingMJTamCSIbrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signalingBlood2014124253829383025498454
   PubMed Web of Science ®Google Scholar
• ByrdJCHillmenPJamesDFResponse: additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinibBlood201512510167325745185
   PubMed Web of Science ®Google Scholar
• LipskyAHFarooquiMZTianXIncidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinibHaematologica2015100121571157826430171
   PubMed Web of Science ®Google Scholar
• O’BrienSFurmanRRCoutreSEIbrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialLancet Oncol2014151485824332241
   PubMed Web of Science ®Google Scholar
• ByrdJCBrownJRBarrientosJCIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaN Engl J Med201437132132324881631
   PubMed Web of Science ®Google Scholar
• FarooquiMZValdezJMartyrSIbrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialLancet Oncol201516216917625555420
   PubMed Web of Science ®Google Scholar
• ByrdJCFurmanRRCoutreSEThree-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibBlood2015125162497250625700432
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govIbrutinib in combination with GA101 (obinutuzumab) in previously untreated chronic lymphocytic leukemia (CLL) patients ClinicalTrials.gov Identifier: NCT02315768. Available from: https://clinicaltrials.gov/ct2/show/NCT02315768?term=NCT+02315768&rank=1Accessed August 12, 2016
   Google Scholar
• O’BrienSMBarrientosJCFlinnIWCombination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II studyJ Clin Oncol201230suppl 156515
   Google Scholar
• ClinicalTrials.govFirst-line therapy with ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA-101) (iFCG) for patients with chronic lymphocytic leukemia (CLL) ClinicalTrials.gov Identifier: NCT02629809. Available from: https://clinicaltrials.gov/ct2/show/NCT02629809Accessed August 12, 2016
   Google Scholar
• WoyachJAFurmanRRLiuTMResistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinibN Engl J Med2014370242286229424869598
   PubMed Web of Science ®Google Scholar